Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.63 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 8/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13806407 | 0.93 | NFE2L2 (0.54) | NFE2L2HRH1HPGDITGB3ITGA2B | |
| SCHEMBL12420835 | 0.86 | NFE2L2 (0.50) | NFE2L2HRH1HPGDITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL2195570 | 0.85 | NFE2L2 (0.49) | NFE2L2HRH1HPGDITGB3ITGA2B | |
| SCHEMBL12735833 | 0.85 | TDP1 (0.56) | HRH1HPGDHRH3 | |
| SCHEMBL13806541 | 0.80 | ROCK1 (0.44) | NFE2L2HRH1HPGDITGB3ITGA2B | |
| SCHEMBL74143 | 0.79 | HRH1 (0.53) | HRH1ITGB3ITGA2BHRH3 | |
| SCHEMBL15651091 | 0.78 | NFE2L2 (0.71) | NFE2L2ITGB3ITGA2BCHEK2 | |
| SCHEMBL20958147 | 0.78 | NFE2L2 (1.00) | NFE2L2HPGDHRH3GRM2 | |
| Hydrochloric Acid SCHEMBL74092 | 0.78 | HRH1 (0.51) | HRH1ITGB3ITGA2BHRH3 | |
| SCHEMBL14795309 | 0.77 | HRH1 (0.54) | HRH1HPGDHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | NFE2L2 1770/4885HRH1 75/4885HPGD 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.